2020
Tendulkar RD, Mian OY. Yes, Nodal Recurrence of Prostate Cancer is Potentially Curable. Int J Radiat Oncol Biol Phys. 2020;106(2):238. doi:10.1016/j.ijrobp.2019.07.016
Tom MC, Reddy CA, Smile TD, et al. Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy. Brachytherapy. 2020;19(1):43‐50. doi:10.1016/j.brachy.2019.10.005
Grivas P, Bismar TA, Alva AS, et al. Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. Urol Oncol. 2020;38(4):262‐268. doi:10.1016/j.urolonc.2019.11.004
Peng LC, Mian OY, Lakshminarayanan P, et al. Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer. Urology. 2020;135:111‐116. doi:10.1016/j.urology.2019.08.014
2019
Ericson KJ, Murthy PB, Bryk DJ, et al. Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer. Clin Adv Hematol Oncol. 2019;17(12):697‐707.
Tom MC, Nguyen JK, Lucianò R, et al. Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy. J Urol. 2019;202(4):710‐716. doi:10.1097/JU.0000000000000316
Balyimez A, Stephans KL, Abazeed ME, Mian OY. The landscape of early carcinogenesis revealed through the lens of integrative genomics, epigenomics, and transcriptomics. J Thorac Dis. 2019;11(6):2188‐2191. doi:10.21037/jtd.2019.06.07
Batista da Costa J, Gibb EA, Bivalacqua TJ, et al. Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clin Cancer Res. 2019;25(13):3908‐3920. doi:10.1158/1078-0432.CCR-18-3558
Purysko AS, Magi-Galluzzi C, Mian OY, et al. Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. Eur Radiol. 2019;29(9):4861‐4870. doi:10.1007/s00330-019-06114-x
Yu JB, Beck TF, Anscher MS, et al. The ASTRO Research Portfolio: Where Do We Go From Here?. Int J Radiat Oncol Biol Phys. 2019;103(2):308‐309. doi:10.1016/j.ijrobp.2018.09.009
Yu JB, Beck TF, Anscher MS, et al. Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio. Int J Radiat Oncol Biol Phys. 2019;103(2):297‐304. doi:10.1016/j.ijrobp.2018.07.2056
Koshkin VS, Garcia JA, Reynolds J, et al. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clin Cancer Res. 2019;25(1):210‐221. doi:10.1158/1078-0432.CCR-18-1278
2018
Cheng Z, Rosati LM, Chen L, et al. Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. Adv Radiat Oncol. 2018;3(4):601‐610. Published 2018 Jul 19. doi:10.1016/j.adro.2018.07.002
Vargas R, Gopal P, Kuzmishin GB, et al. Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. NPJ Precis Oncol. 2018;2:14. Published 2018 Jul 11. doi:10.1038/s41698-018-0060-3
2017
Mian OY, Tendulkar RD, Abazeed ME. The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of origin. Transl Cancer Res. 2017;6(Suppl 9):S1441‐S1445. doi:10.21037/tcr.2017.10.49
Lee J, Mian OY, Le Y, et al. Intraoperative Registered Ultrasound and Fluoroscopy (iRUF) for dose calculation during prostate brachytherapy: Improved accuracy compared to standard ultrasound-based dosimetry. Radiother Oncol. 2017;124(1):61‐67. doi:10.1016/j.radonc.2017.05.018
2016
Lock M, Malayeri AA, Mian OY, Mayr NA, Herman JM, Lo SS. Computed tomography imaging assessment of postexternal beam radiation changes of the liver. Future Oncol. 2016;12(23):2729‐2739. doi:10.2217/fon-2016-0165
Mian OY, Thomas O, Lee JJ, et al. Timely stereotactic body radiotherapy (SBRT) for spine metastases using a rapidly deployable automated planning algorithm. Springerplus. 2016;5(1):1337. Published 2016 Aug 11. doi:10.1186/s40064-016-2961-3
Choflet A, Narang AK, Herald Hoofring L, et al. Prevalence of Substance Use in Patients With Cancer Receiving Radiation Therapy. Clin J Oncol Nurs. 2016;20(4):397‐402. doi:10.1188/16.CJON.397-402
Mian OY, Khattab MH, Hedayati M, et al. GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate. 2016;76(2):199‐206. doi:10.1002/pros.23111
2014
Kuo N, Dehghan E, Deguet A, et al. An image-guidance system for dynamic dose calculation in prostate brachytherapy using ultrasound and fluoroscopy. Med Phys. 2014;41(9):091712. doi:10.1118/1.4893761
Mian OY, Ram AN, Tuli R, Herman JM. Management options in locally advanced pancreatic cancer. Curr Oncol Rep. 2014;16(6):388. doi:10.1007/s11912-014-0388-y
2008
Ginder GD, Gnanapragasam MN, Mian OY. The role of the epigenetic signal, DNA methylation, in gene regulation during erythroid development. Curr Top Dev Biol. 2008;82:85‐116. doi:10.1016/S0070-2153(07)00004-X
2006
Patino WD, Kang JG, Matoba S, Mian OY, Gochuico BR, Hwang PM. Atherosclerotic plaque macrophage transcriptional regulators are expressed in blood and modulated by tristetraprolin. Circ Res. 2006;98(10):1282‐1289. doi:10.1161/01.RES.0000222284.48288.28
2005
Shizukuda Y, Matoba S, Mian OY, Nguyen T, Hwang PM. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem. 2005;273(1-2):25‐32. doi:10.1007/s11010-005-5905-8
Patino WD, Mian OY, Kang JG, et al. Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci U S A. 2005;102(9):3423‐3428. doi:10.1073/pnas.0408032102
2003
Patino WD, Mian OY, Shizukuda Y, Hwang PM. Current and future applications of SAGE to cardiovascular medicine. Trends Cardiovasc Med. 2003;13(4):163‐168. doi:10.1016/s1050-1738(03)00055-0
2002
Patino WD, Mian OY, Hwang PM. Serial analysis of gene expression: technical considerations and applications to cardiovascular biology. Circ Res. 2002;91(7):565‐569. doi:10.1161/01.res.0000036018.76903.18